journal
MENU ▼
Read by QxMD icon Read
search

Chinese Clinical Oncology

journal
https://www.readbyqxmd.com/read/29156891/investigating-the-role-of-tumor-infiltrating-lymphocytes-in-advanced-her2-positive-breast-cancer
#1
EDITORIAL
Stephen J Luen, Sherene Loi
No abstract text is available yet for this article.
November 14, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156890/why-the-results-of-adjuvant-pertuzumab-in-her2-positive-early-breast-cancer-has-been-received-as-a-mitigate-success
#2
EDITORIAL
Xavier Pivot, David G Cox, Joseph Gligorov
No abstract text is available yet for this article.
November 9, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156892/trastuzumab-emtansine-in-her2-positive-metastatic-breast-cancer-what-is-the-best-sequence
#3
EDITORIAL
Francesco Ricci, Christophe Le Tourneau
No abstract text is available yet for this article.
November 6, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156889/chemotherapy-induced-oral-mucositis-prevention-is-possible
#4
E Una Cidon
BACKGROUND: Oral mucositis (OM) is an inflammation of the oral mucosa which occurs in 20-40% of patients receiving conventional chemotherapy (CM). Many different substances have been used separately to treat or prevent OM but no standard procedure has been settled as definitive. We conducted a prospective study to examine whether rinses with a mixture of soluble prednisolone, nystatin and salt water applied before the expected OM appears, would reduce the incidence of grade 2-3 OM in subsequent cycles of CM...
November 3, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156888/chimeric-antigen-receptor-car-t-and-other-t-cell-strategies-for-pancreas-adenocarcinoma
#5
Anna M Varghese
Treatments in metastatic pancreas cancer remain based in cytotoxic chemotherapy, and novel treatment strategies are needed. Building on the emerging role of T cell therapy in hematologic malignancies and our understanding of the underlying biology of pancreas cancer, research is growing in the role of T cell therapy for patients with solid tumors in general and more specifically patients with pancreas cancer. This review will focus on describing the biology of T cell therapy and its current applications in pancreas cancer...
October 24, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156886/advocacy-and-pancreas-cancer-a-new-world
#6
Jane Mahoney Holt, Matthew R Alsante
No abstract text is available yet for this article.
October 20, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156887/technical-aspects-of-pancreaticoduodenectomy-and-their-outcomes
#7
Katherine Giuliano, Aslam Ejaz, Jin He
Pancreatic cancer is the fourth leading cause of cancer-related death in the Unites States and is rising in incidence. For the 15-25% of patients who do not have either metastatic or locally advanced disease, surgical resection with pancreaticoduodenectomy is the standard of care and results in improved 5-year survival of 15-25%. While mortality at high-volume centers is less than 5%, morbidity remains high at approximately 30-45%. This paper reviews technical aspects of pancreaticoduodenectomy and their outcomes...
September 26, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129096/eras-tubeless-michael-haddock-the-past-and-future-of-proton-beam
#8
Bella Poon, Helen Seliman
No abstract text is available yet for this article.
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129095/trastuzumab-biosimilar-in-early-breast-cancer-setting-will-there-be-direct-patient-benefits
#9
Arlene Chan
No abstract text is available yet for this article.
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129094/rational-combination-of-immunotherapy-for-triple-negative-breast-cancer-treatment
#10
Chia-Wei Li, Seung-Oe Lim, Jennifer L Hsu, Mien-Chie Hung
Recent evidence indicates that tumor infiltrating lymphocytes (TILs), including cytotoxic T cells, are present in the tumor microenvironment of triple-negative breast cancers (TNBC). Despite the presence of cytotoxic T cells, these tumors still develop, progress, and metastasize, suggesting evasion of immune response. One mechanism of immunosuppression is the presence of the T cell inhibitory molecule, programmed death protein 1 (PD-1), on infiltrating T cells and its cognate ligand programmed death ligand 1 (PD-L1) on tumor cells, myeloid dendritic cells (DCs), and macrophages, in the tumor microenvironment...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129093/xxxxx
#11
Tomas G Lyons, Geoffrey Y Ku
The poor prognosis for patients with esophagogastric cancers (EGC) requires the development of newer more effective therapies to further improve the treatment outcomes for this disease. Immunotherapy is a novel treatment strategy that is dramatically changing the treatment landscape for several types of cancers. Cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death the programmed death (PD)-1/PD-ligand are essential immune checkpoint inhibitors that suppress T cell activation. Targeting of these immune checkpoints with monoclonal antibodies has shown clinical efficacy in several solid tumors which has led to their approval and use in routine clinical practice...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129092/adenocarcinoma-of-the-esophagus-controversies-and-consensus
#12
David H Ilson
Esophageal cancer, the sixth most common cause of cancer globally, is characterized by the development of early systemic metastatic disease. Adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) is more common in the West. Preoperative chemotherapy or chemoradiotherapy is employed for locally advanced disease with contemporary studies suggesting higher rates of curative resection and reduced rates of local recurrence with the combination of chemotherapy and radiation therapy given prior to surgery...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129091/issues-in-the-management-of-esophageal-cancer-and-geriatric-patients
#13
Elizabeth Won
Esophageal cancer is a disease occurring in older adults and given the aging population, the incidence of cancer in the elderly will continue to rise. However, older patients are less likely to receive treatment for their cancers based on age alone. There are limited data and guidelines for how to manage the older patient population but elderly patients can derive benefit from treatment. This review will describe issues specific to older patients with esophageal cancer with a focus on the utilization of geriatric assessment (GA) tools and how to apply geriatric principles to this cancer patients...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129090/screening-and-prevention-strategies-and-endoscopic-management-of-early-esophageal-cancer
#14
James A Kim, Pari M Shah
Esophageal cancer is the 8th most common cancer worldwide and the 6th most common cause of cancer-related death. Its two main subtypes, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), have varying incidences globally, but recent decades have seen a demonstrated rise of EAC in Western countries whereas ESCC remains highly prevalent in Eastern Africa, Central Asia, and China. Screening interventions have focused on using endoscopy to identify Barrett's esophagus (BE) as a precursor to EAC, and squamous cell dysplasia prior to onset of ESCC...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129089/systemic-therapy-for-esophageal-cancer-chemotherapy
#15
Geoffrey Y Ku
As one-half of patients with esophagogastric cancer (EGC) present with metastatic disease and the majority of patients with locally advanced disease will eventually develop metastatic disease despite multimodality therapy, most patients will receive palliative chemotherapy at some point. The reference first-line regimen consists of a fluoropyrimidine/platinum combination, which is the standard in East Asia, where this disease is endemic. Options include infusional 5-fluorouracil (5-FU), capecitabine, S-1 and other oral 5-FU pro-drugs and cisplatin or oxaliplatin...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129088/systemic-therapy-for-esophagogastric-cancer-targeted-therapies
#16
Tomas G Lyons, Geoffrey Y Ku
The poor prognosis for patients with esophagogastric cancers (EGC) has resulted in an increased focus on the use of targeted agents in this disease. Targets include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), Her2, mammalian target of rapamycin (mTOR), MET, poly (ADP-ribose) polymerase (PARP) and claudin 18.2 (CLDN18.2). Trastuzumab, an anti-Her2 antibody, was approved by the U.S. FDA in 2010 as first-line therapy in combination with chemotherapy for Her2-positive disease...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129087/surgical-management-of-esophageal-cancer
#17
Raj G Vaghjiani, Daniela Molena
Esophageal cancer (EC) is an aggressive malignancy associated with an overall poor prognosis. The specific risk factors for EC vary by histologic type as well as geographic distribution but there is no widely applicable screening strategy to date. Patients can present with vague symptoms which can prove to be a diagnostic challenge. Furthermore, cases tend to present at a late stage, making therapeutic approach difficult. Despite ongoing changes in management strategy, surgery remains the only viable option for cure in early stage malignancy...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129086/the-management-of-localized-esophageal-squamous-cell-carcinoma-western-approach
#18
Neeha Zaidi, Ronan J Kelly
Esophageal cancer remains a significant cause of cancer-related mortality worldwide and carries a poor prognosis both in the locally advanced and metastatic setting. Esophageal squamous cell carcinoma (ESCC) accounts for the majority of esophageal cancers globally, while esophageal adenocarcinoma (EAC) now predominates in the Western world. Historically, clinical trials have not separated the two histologic subtypes, with similar regimens being used for both. This, however, is changing with the recent publication by the Cancer Genome Atlas Research Group confirming that comprehensive analysis reveals ESCC demonstrates frequent genomic amplifications of CCND1 and SOX2 and/or TP63 and biologically are more like head and neck squamous cell carcinomas, whereas EACs strongly resemble the chromosomally unstable variant of gastric cancer...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129085/radiation-techniques-for-esophageal-cancer
#19
Minsi Zhang, Abraham J Wu
Radiotherapy plays a crucial role in the curative management of localized esophageal cancer, both as definitive and preoperative therapy. For definitive therapy, the standard radiation dose is 50.4 Gy in 28 fractions and should be delivered with concurrent chemotherapy. Chemoradiotherapy also has a wellestablished benefit in the preoperative setting, as established in the CROSS randomized trial. Radiation fields are typically generous, to account for subclinical extension of disease along the esophagus and to regional nodes...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129084/preface-on-esophagus-cancer
#20
Geoffrey Y Ku, David H Ilson
No abstract text is available yet for this article.
October 2017: Chinese Clinical Oncology
journal
journal
47887
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"